Prevention of Alzheimer's disease

References

• Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, et al. Effects of rofecoxib or naproxen versus placebo on Alzheimer disease progression: A randomized controlled trial. JAMA 2003; 289: 2819–2826
   PubMed Web of Science ®Google Scholar
• Aisen PS, Schmeidler J, Pasinetti GM. Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology 2002; 58: 1050–1054
   PubMed Web of Science ®Google Scholar
• Anekonda TS. Resveratrol–A boon for treating Alzheimer's disease?. Brain Res Brain Res Rev 2006; 52: 316–326
   PubMed Web of Science ®Google Scholar
• Asthana S, Baker LD, Craft S, Stanczyk FZ, Veith RC, Raskind MA, et al. High-dose estradiol improves cognition for women with AD: Results of a randomized study. Neurology 2001; 57: 605–612
   PubMed Web of Science ®Google Scholar
• Asthana S, Craft S, Baker LD, Raskind MA, Birnbaum RS, Lofgreen CP, et al. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: Results of a placebo-controlled, double-blind, pilot study. Psychoneuroendocrinology 1999; 24: 657–677
   PubMed Web of Science ®Google Scholar
• Bai DL, Tang XC, He XC. Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease. Curr Med Chem 2000; 7: 355–374
   PubMed Web of Science ®Google Scholar
• Ball K, Berch DB, Helmers KF, Jobe JB, Leveck MD, Marsiske M, et al. Effects of cognitive training interventions with older adults: A randomized controlled trial. JAMA 2002; 288: 2271–2281
   PubMed Web of Science ®Google Scholar
• Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6: 916–919
   PubMed Web of Science ®Google Scholar
• Behl C. Alzheimer's disease and oxidative stress: Implications for novel therapeutic approaches. Prog Neurobiol 1999; 57: 301–323
   PubMed Web of Science ®Google Scholar
• Berchtold NC, Chinn G, Chou M, Kesslak JP, Cotman CW. Exercise primes a molecular memory for brain-derived neurotrophic factor protein induction in the rat hippocampus. Neuroscience 2005; 133: 853–861
   PubMed Web of Science ®Google Scholar
• Beresford SA, Johnson KC, Ritenbaugh C, Lasser NL, Snetselaar LG, Black HR, et al. Low-fat dietary pattern and risk of colorectal cancer: The Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 2006; 295: 643–654
   PubMed Web of Science ®Google Scholar
• Berr C, Richard MJ, Roussel AM, Bonithon-Kopp C. Systemic oxidative stress and cognitive performance in the population-based EVA study. Etude du Vieillissement Arteriel. Free Radic Biol Med 1998; 24: 1202–1208
   PubMed Web of Science ®Google Scholar
• Black SE, Wilcock G, Haworth J, Hendrix S, Zavitz K, Binger M, et al. A placebo-controlled, double-blind trial of the selective Abeta42-lowering agent Flurizan in patients with mild to moderate Alzheimer's disease: Efficacy, safety, and follow-on results. Society for Neuroscience, Washington, DC 2005, Program No. 585.6
   Google Scholar
• Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, et al. Use of ramipril in preventing stroke: Double blind randomised trial. BMJ 2002; 324: 699–702
   PubMed Web of Science ®Google Scholar
• Bostom AG, Rosenberg IH, Silbershatz H, Jacques PF, Selhub J, D'Agostino RB, et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: The Framingham Study. Ann Intern Med 1999; 131: 352–355
   PubMed Web of Science ®Google Scholar
• Breitner JC, Gau BA, Welsh KA, Plassman BL, McDonald WM, Helms MJ, et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: Initial results of a co-twin control study. Neurology 1994; 44: 227–232
   PubMed Web of Science ®Google Scholar
• Breitner JC, Zandi PP. Effects of estrogen plus progestin on risk of dementia. JAMA 2003; 290: 1706–1707
   PubMedGoogle Scholar
• Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092–1102
   PubMed Web of Science ®Google Scholar
• Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998; 88: 1337–1342
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control. Public health and aging: Trends in aging–United States and worldwide. Morbidity and Mortality Weekly Report 2003; 52: 101–106
   PubMedGoogle Scholar
• Cherrier MM, Matsumoto AM, Amory JK, Asthana S, Bremner W, Peskind ER, et al. Testosterone improves spatial memory in men with Alzheimer disease and cmild cognitive impairment. Neurology 2005; 64: 2063–2068
   PubMed Web of Science ®Google Scholar
• Christen S, Jiang Q, Shigenaga MK, Ames BN. Analysis of plasma tocopherols alpha, gamma, and 5-nitro-gamma in rats with inflammation by HPLC coulometric detection. Journal of Lipid Research 2002; 43: 1978–1985
   PubMed Web of Science ®Google Scholar
• Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998; 55: 1449–1455
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A pilot study of curcumin and ginkgo for treating Alzheimer's disease; Baum L, Principal Investigator; sponsored by BUPA Foundation and Institute of Chinese Medicine of the Chinese University of Hong Kong. 2006a, Accessed on 22 Mar 2006
   Google Scholar
• ClinicalTrials.gov. Curcumin in patients with mild to moderate Alzheimer's disease; Ringman J., Study Director; sponsored by John Douglas French Foundation and ISOA. 2006b, Accessed on 15 Nov 2006
   Google Scholar
• ClinicalTrials.gov. Effects of ONO-2506PO in patients with Alzheimer's disease. 2006c, Accessed on 22 Dec 2006
   Google Scholar
• ClinicalTrials.gov. Huperzine A in Alzheimer's disease. 2006d, Accessed on 23 Nov 2006
   Google Scholar
• ClinicalTrials.gov. Search ‘rosiglitazone and Alzheimer’. 2006e, Accessed on 23 Nov 2006
   Google Scholar
• Colcombe S, Kramer AF. Fitness effects on the cognitive function of older adults: A meta-analytic study. Psychol Sci 2003; 14: 125–130
   PubMed Web of Science ®Google Scholar
• Commenges D, Scotet V, Renaud S, Jacqmin-Gadda H, Barberger-Gateau P, Dartigues JF. Intake of flavonoids and risk of dementia. Eur J Epidemiol 2000; 16: 357–363
   PubMed Web of Science ®Google Scholar
• Cornelius C, Fastbom J, Winblad B, Viitanen M. Aspirin, NSAIDs, risk of dementia, and influence of the apolipoprotein E epsilon 4 allele in an elderly population. Neuroepidemiology 2004; 23: 135–143
   PubMed Web of Science ®Google Scholar
• Corrada MM, Kawas CH, Hallfrisch J, Muller D, Brookmeyer R. Reduced risk of Alzheimer's disease with high folate intake: The Baltimore Longitudinal Study of Aging. Alzheimer's and Dementia 2006; 1: 11–18
   Google Scholar
• Cotman CW, Berchtold NC. Exercise: A behavioral intervention to enhance brain health and plasticity. Trends Neurosci 2002; 25: 295–301
   PubMed Web of Science ®Google Scholar
• Craft S. Insulin resistance syndrome and Alzheimer's disease: Age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging 2005; 26 Suppl 1: 65–69
   PubMedGoogle Scholar
• DeKosky ST, Fitzpatrick A, Ives DG, Saxton J, Williamson J, Lopez OL, et al. The Ginkgo Evaluation of Memory (GEM) study: Design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia. Contemp Clin Trials 2006; 27: 238–253
   PubMed Web of Science ®Google Scholar
• DuBois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, et al. Cyclooxygenase in biology and disease. FASEB J 1998; 12: 1063–1073
   PubMed Web of Science ®Google Scholar
• Engelhart MJ, Geerlings MI, Ruitenberg A, van Swieten JC, Hofman A, Witteman JC, et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 2002; 287: 3223–3229
   PubMed Web of Science ®Google Scholar
• Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest 2003; 112: 440–449
   PubMed Web of Science ®Google Scholar
• Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ, et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 1989; 262: 2551–2556
   PubMed Web of Science ®Google Scholar
• Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98: 5856–5861
   PubMed Web of Science ®Google Scholar
• Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: A Delphi consensus study. Lancet 2005; 366: 2112–2117
   PubMed Web of Science ®Google Scholar
• Fillenbaum GG, Kuchibhatla MN, Hanlon JT, Artz MB, Pieper CF, Schmader KE, et al. Dementia and Alzheimer's disease in community-dwelling elders taking vitamin C and/or vitamin E. Ann Pharmacother 2005; 39: 2009–2014
   PubMed Web of Science ®Google Scholar
• Fishel MA, Watson GS, Montine, T, Wang Q, Green PS, Kulstad JJ, et al. Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. Arch Neurol 2005; 62: 1539–1544
   PubMed Web of Science ®Google Scholar
• Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, et al. The prevention of dementia with antihypertensive treatment: New evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002; 162: 2046–2052
   PubMed Web of Science ®Google Scholar
• Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347–1351
   PubMed Web of Science ®Google Scholar
• Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005; 64: 1563–1572
   PubMed Web of Science ®Google Scholar
• Fratiglioni L, Paillard-Borg S, Winblad B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol 2004; 3: 343–353
   PubMed Web of Science ®Google Scholar
• Gao S, Hendrie HC, Hall KS, Hui S. The relationships between age, sex, and the incidence of dementia and Alzheimer disease: A meta-analysis. Arch Gen Psychiatry 1998; 55: 809–815
   PubMed Web of Science ®Google Scholar
• Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64: 1553–1562
   PubMed Web of Science ®Google Scholar
• Gold PE, Cahill L, Wenk GL. Ginkgo biloba: A cognitive enhancer?. Psychological Science in the Public Interest 2002; 3: 2–11
   PubMed Web of Science ®Google Scholar
• Goodwin JS, Goodwin JM, Garry PJ. Association between nutritional status and cognitive functioning in a healthy elderly population. JAMA 1983; 249: 2917–2921
   PubMed Web of Science ®Google Scholar
• Guallar E, Hanley DF, Miller ER, III. An editorial update: Annus horribilis for vitamin E. Ann Intern Med 2005; 143: 143–145
   PubMed Web of Science ®Google Scholar
• Guo Z, Fratiglioni L, Viitanen M, Lannfelt L, Basun H, Fastbom J, et al. Apolipoprotein E genotypes and the incidence of Alzheimer's disease among persons aged 75 years and older: Variation by use of antihypertensive medication?. Am J Epidemiol 2001; 153: 225–231
   PubMed Web of Science ®Google Scholar
• Guo Z, Fratiglioni L, Zhu L, Fastbom J, Winblad B, Viitanen M. Occurrence and progression of dementia in a community population aged 75 years and older: Relationship of antihypertensive medication use. Arch Neurol 1999; 56: 991–996
   PubMedGoogle Scholar
• Hajjar I, Schumpert J, Hirth V, Wieland D, Eleazer GP. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci 2002; 57: M414–M418
   PubMed Web of Science ®Google Scholar
• Harats D, Chevion S, Nahir M, Norman Y, Sagee O, Berry EM. Citrus fruit supplementation reduces lipoprotein oxidation in young men ingesting a diet high in saturated fat: Presumptive evidence for an interaction between vitamins C and E in vivo. Am J Clin Nutr 1998; 67: 240–245
   PubMed Web of Science ®Google Scholar
• Hayden KM, Welsh-Bohmer KA, Wengreen HJ, Zandi PP, Lyketsos C, Breitner JC. Risk of mortality with vitamin E supplements. The Cache County Study. Am J Med 2007; 120: 180–184
   PubMedGoogle Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7–22
   PubMed Web of Science ®Google Scholar
• Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: Prevalence estimates using the 2000 census. Arch Neurol 2003; 60: 1119–1122
   PubMed Web of Science ®Google Scholar
• Henderson V, Paganini-Hill A, Miller BL, Elble RJ, Reyes PF, Shoupe D, et al. Estrogen for Alzheimer's disease in women: Randomized, double-blind, placebo-controlled trial. Neurology 2000; 54: 295–301
   PubMed Web of Science ®Google Scholar
• Hendrie HC. Epidemiology of dementia and Alzheimer's disease. Am J Geriatr Psychiatry 1998; 6: S3–18
   PubMed Web of Science ®Google Scholar
• Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van HF, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997; 349: 151–154
   PubMed Web of Science ®Google Scholar
• Hogervorst E, Bandelow S, Moffat SD. Increasing testosterone levels and effects on cognitive functions in elderly men and women: A review. Curr Drug Targets CNS Neurol Disord 2005; 4: 531–540
   PubMedGoogle Scholar
• Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials. BMJ 1998; 316: 894–898
   PubMedGoogle Scholar
• Howard BV, Van HL, Hsia J, Manson JE, Stefanick ML, Wassertheil-Smoller S, et al. Low-fat dietary pattern and risk of cardiovascular disease: The Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 2006; 295: 655–666
   PubMed Web of Science ®Google Scholar
• Huang TL, Zandi PP, Tucker KL, Fitzpatrick AL, Kuller LH, Fried L, et al. Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. Neurology 2005; 65: 1409–1414
   PubMed Web of Science ®Google Scholar
• In 't Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001; 345: 1515–1521
   PubMed Web of Science ®Google Scholar
• In't Veld BA, Ruitenberg A, Hofman A, Stricker BH, Breteler MM. Antihypertensive drugs and incidence of dementia: The Rotterdam study. Neurobiol Aging 2001; 22: 407–412
   PubMed Web of Science ®Google Scholar
• Jama JW, Launer LJ, Witteman JC, den Breeijen JH, Breteler MM, Grobbee DE, et al. Dietary antioxidants and cognitive function in a population-based sample of older persons. The Rotterdam study. Am J Epidemiol 1996; 144: 275–280
   PubMed Web of Science ®Google Scholar
• Jiang Q, Lykkesfeldt J, Shigenaga MK, Shigeno ET, Christen S, Ames BN. Gamma-tocopherol supplementation inhibits protein nitration and ascorbate oxidation in rats with inflammation. Free Radic Biol Med 2002; 33: 1534–1542
   PubMed Web of Science ®Google Scholar
• Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging. Neurology 1997; 48: 1517–1521
   PubMed Web of Science ®Google Scholar
• Kawas CH. Diet and the risk for Alzheimer's disease. Ann Neurol 2006; 59: 877–879
   PubMedGoogle Scholar
• Khachaturian AS, Zandi PP, Lyketsos CG, Hayden KM, Skoog I, Norton MC, et al. Antihypertensive medication use and incident Alzheimer disease: The Cache County Study. Arch Neurol 2006; 63: 686–692
   PubMed Web of Science ®Google Scholar
• Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, et al. Midlife vascular risk factors and Alzheimer's disease in later life: Longitudinal, population based study. BMJ 2001; 322: 1447–1451
   PubMed Web of Science ®Google Scholar
• Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kareholt I, Winblad B, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 2005; 62: 1556–1560
   PubMed Web of Science ®Google Scholar
• Kleijnen J, Knipschild P. Ginkgo biloba for cerebral insufficiency. British Journal of Clinical Pharmacology 1992; 34: 352–358
   PubMed Web of Science ®Google Scholar
• La RA, Koehler KM, Wayne SJ, Chiulli SJ, Haaland KY, Garry PJ. Nutritional status and cognitive functioning in a normally aging sample: A 6-year reassessment. Am J Clin Nutr 1997; 65: 20–29
   PubMed Web of Science ®Google Scholar
• Launer LJ. Demonstrating the case that AD is a vascular disease: Epidemiologic evidence. Ageing Res Rev 2002; 1: 61–77
   PubMed Web of Science ®Google Scholar
• Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-Mirnics Z, Lee VM, et al. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 2005; 120: 701–713
   PubMed Web of Science ®Google Scholar
• Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA 1997; 278: 1327–1332
   PubMed Web of Science ®Google Scholar
• Li G, Higdon R, Kukull WA, Peskind E, Van Valen MK, Tsuang D, et al. Statin therapy and risk of dementia in the elderly: A community-based prospective cohort study. Neurology 2004; 63: 1624–1628
   PubMed Web of Science ®Google Scholar
• Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001; 21: 8370–8377
   PubMed Web of Science ®Google Scholar
• Lindsay J, Laurin D, Verreault R, Hebert R, Helliwell B, Hill GB, et al. Risk factors for Alzheimer's disease: A prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 2002; 156: 445–453
   PubMed Web of Science ®Google Scholar
• Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875–886
   PubMed Web of Science ®Google Scholar
• Luchsinger JA, Tang MX, Shea S, Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 2003; 60: 203–208
   PubMed Web of Science ®Google Scholar
• Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004; 63: 1187–1192
   PubMed Web of Science ®Google Scholar
• Martin BK, Meinert CL, Breitner JC. Double placebo design in a prevention trial for Alzheimer's disease. Control Clin Trials 2002; 23: 93–99
   PubMedGoogle Scholar
• Masaki KH, Losonczy KG, Izmirlian G, Foley DJ, Ross GW, Petrovitch H, et al. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 2000; 54: 1265–1272
   PubMed Web of Science ®Google Scholar
• McCaddon A, Davies G, Hudson P, Tandy S, Cattell H. Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry 1998; 13: 235–239
   PubMed Web of Science ®Google Scholar
• McGeer PL, McGeer E, Rogers J, Sibley J. Anti-inflammatory drugs and Alzheimer disease. Lancet 1990; 335: 1037
   PubMed Web of Science ®Google Scholar
• Meade EA, Smith WL, Dewitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993; 268: 6610–6614
   PubMed Web of Science ®Google Scholar
• Mendelsohn AB, Belle SH, Stoehr GP, Ganguli M. Use of antioxidant supplements and its association with cognitive function in a rural elderly cohort: The MoVIES project. Monongahela Valley Independent Elders Survey. Am J Epidemiol 1998; 148: 38–44
   PubMed Web of Science ®Google Scholar
• Miller ER, III, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142: 37–46
   PubMed Web of Science ®Google Scholar
• Moffat SD, Zonderman AB, Metter EJ, Kawas C, Blackman MR, Harman SM, et al. Free testosterone and risk for Alzheimer disease in older men. Neurology 2004; 62: 188–193
   PubMed Web of Science ®Google Scholar
• Molloy AM, Scott JM. Folates and prevention of disease. Public Health Nutrition 2001; 4: 601–609
   PubMed Web of Science ®Google Scholar
• Mori T, Town T, Tan J, Yada N, Horikoshi Y, Yamamoto J, et al. Arundic Acid ameliorates cerebral amyloidosis and gliosis in Alzheimer transgenic mice. J Pharmacol Exp Ther 2006; 318: 571–578
   PubMed Web of Science ®Google Scholar
• Morris MC, Beckett LA, Scherr PA, Hebert LE, Bennett DA, Field TS, et al. Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alzheimer Dis Assoc Disord 1998; 12: 121–126
   PubMed Web of Science ®Google Scholar
• Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Aggarwal N, et al. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 2002; 287: 3230–3237
   PubMed Web of Science ®Google Scholar
• Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Wilson RS, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 2003; 60: 940–946
   PubMed Web of Science ®Google Scholar
• Morris MC, Evans DA, Schneider JA, Tangney CC, Bienias JL, Aggarwal NT. Dietary folate and vitamins B-12 and B-6 not associated with incident Alzheimer's disease. J Alzheimers Dis 2006; 9: 435–443
   PubMed Web of Science ®Google Scholar
• Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 2000; 283: 1007–1015
   PubMed Web of Science ®Google Scholar
• Ng TP, Chiam PC, Lee T, Chua HC, Lim L, Kua EH. Curry consumption and cognitive function in the elderly. Am J Epidemiol 2006; 164: 898–906
   PubMed Web of Science ®Google Scholar
• Oken BS, Storzbach DM, Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 1998; 55: 1409–1415
   PubMed Web of Science ®Google Scholar
• Orgogozo JM, Dartigues JF, Lafont S, Letenneur L, Commenges D, Salamon R, et al. Wine consumption and dementia in the elderly: A prospective community study in the Bordeaux area. Rev Neurol (Paris) 1997; 153: 185–192
   PubMed Web of Science ®Google Scholar
• Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003; 61: 46–54
   PubMed Web of Science ®Google Scholar
• Paleologos M, Cumming RG, Lazarus R. Cohort study of vitamin C intake and cognitive impairment. Am J Epidemiol 1998; 148: 45–50
   PubMed Web of Science ®Google Scholar
• Panza F, Solfrizzi V, Colacicco AM, D'Introno A, Capurso C, Torres F, et al. Mediterranean diet and cognitive decline. Public Health Nutrition 2004; 7: 959–963
   PubMed Web of Science ®Google Scholar
• Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 2002; 51: 1256–1262
   PubMed Web of Science ®Google Scholar
• Perrig WJ, Perrig P, Stahelin HB. The relation between antioxidants and memory performance in the old and very old. J Am Geriatr Soc 1997; 45: 718–724
   PubMed Web of Science ®Google Scholar
• Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352: 2379–2388
   PubMed Web of Science ®Google Scholar
• Podewils LJ, Guallar E, Kuller LH, Fried LP, Lopez OL, Carlson M, et al. Physical activity, APOE genotype, and dementia risk: Findings from the Cardiovascular Health Cognition Study. Am J Epidemiol 2005; 161: 639–651
   PubMed Web of Science ®Google Scholar
• Prince M, Lewis G, Bird A, Blizard R, Mann A. A longitudinal study of factors predicting change in cognitive test scores over time, in an older hypertensive population. Psychol Med 1996; 26: 555–568
   PubMed Web of Science ®Google Scholar
• Razay G, Vreugdenhil A, Wilcock G. Obesity, abdominal obesity and Alzheimer disease. Dement Geriatr Cogn Disord 2006; 22: 173–176
   PubMedGoogle Scholar
• Rea TD, Breitner JC, Psaty BM, Fitzpatrick A, Lopez OL, Newman A, et al. Statin use and the risk of incident dementia: The Cardiovascular Health Study. Arch Neurol 2005; 62: 1047–1051
   PubMed Web of Science ®Google Scholar
• Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 2000; 7: 321–331
   PubMed Web of Science ®Google Scholar
• Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, et al. Rofecoxib: No effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 2004; 62: 66–71
   PubMed Web of Science ®Google Scholar
• Reitz C, Tang MX, Luchsinger J, Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol 2004; 61: 705–714
   PubMed Web of Science ®Google Scholar
• Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 2006; 6: 246–254
   PubMed Web of Science ®Google Scholar
• Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verreault R, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002; 59: 223–227
   PubMed Web of Science ®Google Scholar
• Rodriguez EG, Dodge HH, Birzescu MA, Stoehr GP, Ganguli M. Use of lipid-lowering drugs in older adults with and without dementia: A community-based epidemiological study. J Am Geriatr Soc 2002; 50: 1852–1856
   PubMed Web of Science ®Google Scholar
• Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993; 43: 1609–1611
   PubMed Web of Science ®Google Scholar
• Rovio S, Kareholt I, Helkala EL, Viitanen M, Winblad B, Tuomilehto J, et al. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neuro 2005; 4: 705–711
   PubMed Web of Science ®Google Scholar
• Sadowski M, Pankiewicz J, Scholtzova H, Li YS, Quartermain D, Duff K, et al. Links between the pathology of Alzheimer's disease and vascular dementia. Neurochem Res 2004; 29: 1257–1266
   PubMed Web of Science ®Google Scholar
• Sainati S, Ingram D, Talwalker S, Geis G. Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's Disease. In 6th International Stockholm-Springfield Symposium of Advances in Alzheimer's Therapy;, StockholmSweden 2000
   Google Scholar
• Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997; 336: 1216–1222
   PubMed Web of Science ®Google Scholar
• Santanello NC, Barber BL, Applegate WB, Elam J, Curtis C, Hunninghake DB, et al. Effect of pharmacologic lipid lowering on health-related quality of life in older persons: Results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study. J Am Geriatr Soc 1997; 45: 8–14
   PubMed Web of Science ®Google Scholar
• Scarmeas N, Stern Y, Tang MX, Mayeux R, Luchsinger JA. Mediterranean diet and risk for Alzheimer's disease. Ann Neurol 2006; 59: 912–921
   PubMed Web of Science ®Google Scholar
• Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, Robins SJ, Au R, et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: The Framingham heart study. Arch Neurol 2006; 63: 1545–1550
   PubMed Web of Science ®Google Scholar
• Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999; 53: 197–201
   PubMed Web of Science ®Google Scholar
• Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173–177
   PubMed Web of Science ®Google Scholar
• Schneider LS, DeKosky ST, Farlow MR, Tariot PN, Hoerr R, Kieser M. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Curr Alzheimer Res 2005; 2: 541–551
   PubMedGoogle Scholar
• Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PW, Belanger AJ, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995; 332: 286–291
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. Alzheimer disease: Mechanistic understanding predicts novel therapies. Ann Intern Med 2004; 627–638, 20, 140
   PubMedGoogle Scholar
• Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346: 476–483
   PubMed Web of Science ®Google Scholar
• SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255–3264
   PubMed Web of Science ®Google Scholar
• Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002; 360: 1623–1630
   PubMed Web of Science ®Google Scholar
• Shumaker SA, Legault C, Coker LH. Behavior-based interventions to enhance cognitive functioning and independence in older adults. JAMA 2006; 296: 2852–2854
   PubMed Web of Science ®Google Scholar
• Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004; 291: 2947–2958
   PubMed Web of Science ®Google Scholar
• Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial. JAMA 2003; 289: 2651–2662
   PubMed Web of Science ®Google Scholar
• Skoog I, Gustafson D. HRT and dementia. J Epidemiol Biostat 1999; 4: 227–251
   PubMedGoogle Scholar
• Skoog I, Gustafson D. Update on hypertension and Alzheimer's disease. Neurol Res 2006; 28: 605–611
   PubMed Web of Science ®Google Scholar
• Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997; 277: 813–817
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071–1080
   PubMed Web of Science ®Google Scholar
• Sparks DL, Sabbagh M, Connor D, Soares H, Lopez J, Stankovic G, et al. Statin therapy in Alzheimer's disease. Acta Neurol Scand Suppl 2006; 185: 78–86
   PubMedGoogle Scholar
• Stern Y. Cognitive reserve and Alzheimer disease. Alzheimer Dis Assoc Disord 2006; 20: S69–S74
   PubMed Web of Science ®Google Scholar
• Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997; 48: 626–632
   PubMed Web of Science ®Google Scholar
• Szekely CA, Breitner JC, Fitzpatrick AL, Rea TD, Psaty BM, Kuller LH, et al. NSAID use and dementia risk in the Cardiovascular Health Study: Role of APOE and NSAID type. Neurology. Epub ahead of print. 2004, (in press)
   Google Scholar
• Szekely CA, Thorne JE, Zandi PP, Ek M, Messias E, Breitner JC, et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: A systematic review. Neuroepidemiology 2004; 23: 159–169
   PubMed Web of Science ®Google Scholar
• Szekely CA, Town T, Zandi PP. NSAIDs for the chemoprevention of Alzheimer's disease. Inflammation in the Pathogenesis of Chronic Diseases: The COX-2 controversy. Biomedical series, RE Harris. Chapter 11, Springer, DordrechtThe Netherlands 2007; 42
   Google Scholar
• Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996; 348: 429–432
   PubMed Web of Science ®Google Scholar
• Thal LJ. Prevention of Alzheimer disease. Alzheimer Dis Assoc Disord 2006; 20: S97–S99
   PubMed Web of Science ®Google Scholar
• Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005; 30: 1204–1215
   PubMed Web of Science ®Google Scholar
• Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003; 163: 1069–1075
   PubMed Web of Science ®Google Scholar
• US Census Bureau. 2004, Annual projections of the resident population by age, sex, race, and hispanic origin: Lowest, middle, highest series and zero international migration series, 1999 to 2100
   Google Scholar
• Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232–235
   PubMedGoogle Scholar
• Vanhanen M, Koivisto K, Moilanen L, Helkala EL, Hanninen T, Soininen H, et al. Association of metabolic syndrome with Alzheimer disease: A population-based study. Neurology 2006; 67: 843–847
   PubMed Web of Science ®Google Scholar
• Vellas B, Andrieu S, Ousset PJ, Ouzid M, Mathiex-Fortunet H. The GuidAge study: Methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761(R) for prevention of Alzheimer disease in patients over 70 with a memory complaint. Neurology 2006; 67: S6–S11
   Google Scholar
• Wang PN, Liao SQ, Liu RS, Liu CY, Chao HT, Lu SR, et al. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: A controlled study. Neurology 2000; 54: 2061–2066
   PubMed Web of Science ®Google Scholar
• Wang R, Tang XC. Neuroprotective effects of huperzine A. A natural cholinesterase inhibitor for the treatment of Alzheimer's disease. Neurosignals 2005; 14: 71–82
   PubMed Web of Science ®Google Scholar
• Wang R, Yan H, Tang XC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin 2006; 27: 1–26
   PubMed Web of Science ®Google Scholar
• Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: A preliminary study. Am J Geriatr Psychiatry 2005; 13: 950–958
   PubMed Web of Science ®Google Scholar
• Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001; 414: 212–216
   PubMed Web of Science ®Google Scholar
• Weiner HL, Frenkel D. Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol 2006; 6: 404–416
   PubMed Web of Science ®Google Scholar
• White AR, Huang X, Jobling MF, Barrow CJ, Beyreuther K, Masters CL, et al. Homocysteine potentiates copper- and amyloid beta peptide-mediated toxicity in primary neuronal cultures: Possible risk factors in the Alzheimer's-type neurodegenerative pathways. J Neurochem 2001; 76: 1509–1520
   PubMed Web of Science ®Google Scholar
• Willis SL, Tennstedt SL, Marsiske M, Ball K, Elias J, Koepke KM, et al. Long-term effects of cognitive training on everyday functional outcomes in older adults. JAMA 2006; 296: 2805–2814
   PubMed Web of Science ®Google Scholar
• Wolkowitz OM, Kramer JH, Reus VI, Costa MM, Yaffe K, Walton P, et al. DHEA treatment of Alzheimer's disease: A randomized, double-blind, placebo-controlled study. Neurology 2003; 60: 1071–1076
   PubMedGoogle Scholar
• Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57: 1439–1443
   PubMed Web of Science ®Google Scholar
• Yaffe K, Krueger K, Cummings SR, Blackwell T, Henderson VW, Sarkar S, et al. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: The Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry 2005; 162: 683–690
   PubMed Web of Science ®Google Scholar
• Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005; 280: 5892–5901
   PubMed Web of Science ®Google Scholar
• Yip AG, Green RC, Huyck M, Cupples LA, Farrer LA. Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: The MIRAGE Study. BMC.Geriatr. 2005; 5: 2
   PubMedGoogle Scholar
• Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106–1118
   PubMed Web of Science ®Google Scholar
• Yoshitake T, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, et al. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: The Hisayama Study. Neurology 1995; 45: 1161–1168
   PubMed Web of Science ®Google Scholar
• Zandi PP, Anthony JC, Hayden KM, Mehta K, Mayer L, Breitner JC. Reduced incidence of AD with NSAID but not H2 receptor antagonists: The Cache County Study. Neurology 2002a; 59: 880–886
   PubMed Web of Science ®Google Scholar
• Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: The Cache County Study. Arch Neurol 2004; 61: 82–88
   PubMed Web of Science ®Google Scholar
• Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: The Cache County Study. JAMA 2002b; 288: 2123–2129
   PubMed Web of Science ®Google Scholar
• Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, et al. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 2005; 62: 217–224
   PubMed Web of Science ®Google Scholar